MedPage Today September 16, 2024
— Researcher discusses weight outcomes for those taking semaglutide or liraglutide
In this video interview, Hamlet Gasoyan, PhD, staff investigator at the Cleveland Clinic’s Center for Value-Based Care Research, discusses his recent study in JAMA Network Open that looked at the weight outcomes and factors associated with clinically meaningful weight loss at 1 year among patients with obesity receiving the GLP-1 agonists semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda).
The following is a transcript of his remarks:
Recently, GLP-1 receptor agonist medications have been prescribed more commonly, in part due to their ability to produce clinically significant weight loss.
And we know we have the randomized controlled trial data with robust efficacy, but outside of randomized controlled trial data, the...
Today's Sponsors
Today's Sponsor